A Study of IBI302 in Patients With nAMD

Inclusion criteria

• Male or female patient ≥ 50 yrs. of age.
• Active subfoveal or parafoveal CNV secondary to neovascular AMD.
• BCVA score of 24-73 letters using ETDRS charts in the study eye.
• Willing and able to sign informed consent form and comply with visit and study procedures per protocol.

Exclusion criteria

• Concomitant diseases that may cause subjects fail to respond to the treatment or confuse the interpretation of the study results;
• Presence of uncontrolled glaucoma in the study eye (defined as IOP≥25mmHg despite the standardized treatment);
• Presence of active intraocular or periocular inflammation or infection;
• Prior any treatment of following in the study eye:

• Anti-VEGF therapy or anti-complement therapy within 3 months prior to screening;
• Laser photocoagulation within 3 months prior to screening;
• Photodynamic therapy or vitreoretinal surgery;
• Intraocular glucocorticoid injection within 6 months prior to enrollment;
• Presence of any systemic disease: including but not limited toactive infections (such as active viral hepatitis); unstable angina; cerebrovascular accident or transient cerebral ischemia (within 6 months prior to selection); myocardial infarction (within 6 months prior to selection); serious arrhythmia requiring medical treatment; liver, kidney or metabolic diseases; or malignant tumor;
• History of severe hypersensitivity/allergy to active ingredients or any excipients of the study drug, or fluorescein and povidone iodine;
• Pregnant or lactating women or women preparing to become pregnant or breastfeeding during the study period;
• Participated in any clinical study of any other drug within three months prior to enrollment, or attempted to participate in other drug trials during the study;
• Other conditions unsuitable for enrollment judged by investigators